Redipor Success Drives Cherwell Cleanroom Expansion
Cherwell Laboratories, leading supplier of microbiology media and instruments for pharmaceutical and related industries, is continuing with the investment and expansion programme of its cleanroom production facilities. To increase capacity for future demand from Cherwell’s ever growing customer base, Phase II of the expansion programme will boost Redipor microbiological prepared media plate filling and bottle production capabilities. The new cleanroom facility will be further extended by 230 m2 to more than 950 m2.
Once Phase II is completed in early 2014, Cherwell’s facilities will have doubled in size since July 2012. Phase I delivered new inspection and packing facilities to maintain stringent quality requirements in media preparation prior to Phase II’s increase in Redipor production facilities. Uniquely, to ensure utmost quality Cherwell do not package Redipor products straight from the filling line but first hold them to condition, additionally all products then undergo 100% inspection before final packing.
Demand for Cherwell’s Redipor products continues to rise as new customers experience the benefits of a flexible and reliable supply of these exceptionally high-quality prepared media products. Cherwell’s ability to deliver high volume efficiency with small volume flexibility has helped to increase its market share and develop more export markets, such as Poland. Careful selection of new partners in mainland Europe, has also contributed to securing new customers keen to benefit from a full adaptable service for their industrial microbiological prepared media.
Andy Whittard, Managing Director, Cherwell Laboratories, provided further insight into the reasons for Cherwell’s expanding market. “Despite growing interest in rapid methods, the traditional methods for environmental monitoring are still the most widely used and will continue to be for many years to come. This, coupled with some customers’ movement back to UK and European-based manufacturing, is seeing demand for prepared media continue to increase.”
As Cherwell’s production volumes increase from the current 6.5 million agar plates annually, the company will continue to add to its workforce to maintain its efficiency in supply. Cherwell has already recruited five new staff members since the completion of Phase I, with three additional new starters anticipated before the end of 2013.
“Phase II of our cleanroom extension will provide additional manufacturing space to allow us to invest in further production equipment, such as large scale plate filling systems, media preparators and autoclaves,” added Andy Whittard. “By carefully planning and controlling the works around our own production schedules and with our contractor, Envair Projects, we aim to minimise any impact to customers and product lead times.”
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...